Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization
    Meeting Abstract

    Wen, P.; Trippa, L.; Lee, E.; Fell, G.; Rahman, R.; Arrillaga-Romany, I.; Touat, M.; McCluskey, C.; Brunno, J.; Gaffey, S.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Activity of larotrectinib in tropomyosin receptor kinase (TRK) fusion cancer patients with central nervous system (CNS) metastases
    Meeting Abstract

    Patel, J. D.; Farago, A. F.; Hong, D. S.; Lassen, U. N.; Leyvraz, S.; Park, K.; Sohal, D. P. S.; Solomon, B.; Reeves, J. A.; Dima, L.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Maintenance chemotherapy using bevacizumab for neurofibromatosis 2 patients with hearing loss and progressive vestibular schwannomas: An NF Clinical Trials Consortium Study (NF104)
    Meeting Abstract

    Plotkin, S.; Tonsgard, J.; Ullrich, N.; Allen, J.; Blakeley, J.; Dhall, G.; Campian, J.; Clapp, W.; Fisher, M.; Cutter, G.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • CC-115 in newly diagnosed MGMT unmethylated glioblastoma in the individualized screening trial of innovative glioblastoma therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial
    Meeting Abstract

    Rahman, R.; Trippa, L.; Fell, G.; Lee, E.; Arrillaga-Romany, I.; Touat, M.; McCluskey, C.; Brunno, J.; Gaffey, S.; Drappatz, J.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Diffusion MR imaging derived apparent diffusion coefficient as a potential biomarker of clinical outcome in recurrent central nervous system lymphoma
    Meeting Abstract

    Ho, K. W.; Nosov, A.; Young, R.; Grommes, C.
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • The integration of a liquid biopsy program into the care of pediatric brain tumor patients
    Meeting Abstract

    Miller, A.; Szalontay, L.; Ahmad, H.; Bouvier, N.; Rodriguez-Sanchez, I.; Bale, T.; Benayed, R.; Arcila, M.; Donzelli, M.; Dunkel, I.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Planned-use glucarpidase for outpatient high dose methotrexate (HD-MTX) administration in patients with CNS lymphoma (CNSL) during the COVID-19 pandemic
    Meeting Abstract

    Schaff, L.; Lobbous, M.; Bozza, A.; Carlow, D.; Nabors, L.; Grommes, C.
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Preliminary results of a phase II study of nivolumab with hypofractionated re-radiation and bevacizumab for recurrent MGMT methylated glioblastoma
    Meeting Abstract

    Grommes, C.; Mehta, M.; Miller, A.; Daras, M.; Piotrowski, A.; Boire, A.; Butler, B.; Stone, J.; Pentsova, E.; Kotecha, R.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • PHASE II and biomarker study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma patients
    Meeting Abstract

    Reardon, D.; Molinaro, A.; Peters, K.; Clarke, J.; Jordan, J.; de Groot, J.; Nghiemphu, P.; Kaley, T.; Colman, H.; McCluskey, C.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTC) in cerebrospinal fluid (CSF) as a predictor of survival in CNS metastases
    Meeting Abstract

    Diaz, M.; Singh, P.; Kotchetkov, I.; Skakodub, A.; Reiner, A.; Panageas, K.; Ramanathan, L.; Pentsova, E.
    Neuro-Oncology (2020)

    Fulltext@MSK | Save